Home > Insider Trading > Filing (0001415889-21-002207)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1411906	Ampio Pharmaceuticals Inc.	AMPE	Pharmaceutical Preparations (2834)	260179592

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1717673	Holli Cherevka	C/O Ampio Pharmaceuticals, Inc. 373 Inverness Parkway, Suite 200 Englewood CO 80112	Chief Operating Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-04-27	30,000	$0.51	30,000	No	4	M	Direct
Common Stock	Acquisiton	2021-04-27	44,631	$0.51	74,631	No	4	M	Direct
Common Stock	Disposition	2021-04-27	74,631	$2.00	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-04-27	30,000	$0.51	30,000	$0.51
Common Stock	Stock Option (Right to Buy)	Disposition	2021-04-27	44,631	$0.51	44,631	$0.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2027-08-08	No	4	M	Direct
155,369		2029-09-16	No	4	M	Direct

Footnotes

The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 12, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.005, inclusive. The reporting person undertakes to provide to Ampio Pharmaceuticals, Inc., any security holder of Ampio Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Options were granted and previously reported on a Form 4 filed on September 21, 2017, where all of the options reported vested and became exercisable immediately.
Options were granted and previously reported on a Form 4 filed on September 18, 2019, where 50% of the options awarded vested and became exercisable on the grant date of September 16, 2019 and the other 50% of the options awarded vested and became exercisable on the first anniversary of the grant date.